Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma.
Advances in chemotherapy have led to a favorable long-term prognosis in approximately 50% of patients with aggressive non-Hodgkin lymphoma (NHL). However, the remaining patients do not enjoy such prolonged survival after standard treatment. New prognostic factors are needed to define this poor-prognosis group and to plan an appropriate treatment strategy. It has been reported that serum nm23-H1 protein may be a new prognostic factor for aggressive NHL. In the present study involving multiple institutions and a large number of patients, the level of nm23-H1 protein was compared among different types of lymphoma; it was lowest for indolent lymphoma, followed by aggressive lymphoma and then highly aggressive lymphoma. In addition, patients with aggressive NHL and higher nm23-H1 levels had worse overall and progression-free survival rates than those with lower nm23-H1 levels. The nm23-H1 level was also compared between patients with diffuse large B-cell lymphoma and patients with peripheral T-cell lymphoma. The results suggest that the level of nm23-H1 could serve as a prognostic factor in both groups. Moreover, the prognosis of lymphoma patients could be ascertained even more precisely by combining soluble interleukin-2 receptor or soluble CD44 and nm23-H1 levels. A multivariate analysis confirmed that the nm23-H1 level is an independent and important prognostic factor in aggressive NHL. Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma.
Niitsu
N
N
First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama. nniitsu@med.kitasato-u.ac.jp
Okabe-Kado
J
J
Okamoto
M
M
Takagi
T
T
Yoshida
T
T
Aoki
S
S
Hirano
M
M
Honma
Y
Y
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005615:Freezing; D006801:Humans; D018960:Hyaluronan Receptors / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D020559:Monomeric GTP-Binding Proteins / Q000097:blood*; D054778:NM23 Nucleoside Diphosphate Kinases; D009701:Nucleoside-Diphosphate Kinase; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood; D015996:Survival Rate; D014157:Transcription Factors / Q000097:blood*
D000951:Antigens, Neoplasm; D015415:Biomarkers; D018960:Hyaluronan Receptors; D054778:NM23 Nucleoside Diphosphate Kinases; D015375:Receptors, Interleukin-2; D014157:Transcription Factors; C517938:NME1 protein, human; D009701:Nucleoside-Diphosphate Kinase; D020559:Monomeric GTP-Binding Proteins